WO2004113277A8 - Procedes et compositions de traitement de maladies associees aux amyloides - Google Patents

Procedes et compositions de traitement de maladies associees aux amyloides

Info

Publication number
WO2004113277A8
WO2004113277A8 PCT/IB2004/002337 IB2004002337W WO2004113277A8 WO 2004113277 A8 WO2004113277 A8 WO 2004113277A8 IB 2004002337 W IB2004002337 W IB 2004002337W WO 2004113277 A8 WO2004113277 A8 WO 2004113277A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
related diseases
treating amyloid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/002337
Other languages
English (en)
Other versions
WO2004113277A3 (fr
WO2004113277A2 (fr
Inventor
Xianqi Kong
Francine Gervais
Walter A Szarek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Bellus Health International Ltd
Original Assignee
Queens University at Kingston
Neurochem International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/871,365 external-priority patent/US7244764B2/en
Priority claimed from US10/871,514 external-priority patent/US7414076B2/en
Priority to CA002529256A priority Critical patent/CA2529256A1/fr
Application filed by Queens University at Kingston, Neurochem International Ltd filed Critical Queens University at Kingston
Priority to EP04743998A priority patent/EP1658264A2/fr
Priority to JP2006516597A priority patent/JP2007516938A/ja
Priority to AU2004249527A priority patent/AU2004249527A1/en
Priority to MXPA05013977A priority patent/MXPA05013977A/es
Publication of WO2004113277A2 publication Critical patent/WO2004113277A2/fr
Publication of WO2004113277A8 publication Critical patent/WO2004113277A8/fr
Publication of WO2004113277A3 publication Critical patent/WO2004113277A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/69—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/02—Thiosulfates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne des procédés, des composés, des compositions pharmaceutiques et des kits pour traiter ou prévenir les maladies associées aux amyloïdes.
PCT/IB2004/002337 2003-06-23 2004-06-21 Procedes et compositions de traitement de maladies associees aux amyloides Ceased WO2004113277A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA05013977A MXPA05013977A (es) 2003-06-23 2004-06-21 Metodos y composiciones para tratar enfermedades relacionadas con amiloide.
AU2004249527A AU2004249527A1 (en) 2003-06-23 2004-06-21 Methods and compositions for treating amyloid-related diseases
CA002529256A CA2529256A1 (fr) 2003-06-23 2004-06-21 Procedes et compositions de traitement de maladies associees aux amyloides
EP04743998A EP1658264A2 (fr) 2003-06-23 2004-06-21 Procedes et compositions de traitement de maladies associees aux amyloides
JP2006516597A JP2007516938A (ja) 2003-06-23 2004-06-21 アミロイド関連疾患を治療するための方法および組成物

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US48090603P 2003-06-23 2003-06-23
US60/480,906 2003-06-23
US51204703P 2003-10-17 2003-10-17
US60/512,047 2003-10-17
US10/871,514 2004-06-18
US10/871,365 US7244764B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,365 2004-06-18
US10/871,514 US7414076B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases

Publications (3)

Publication Number Publication Date
WO2004113277A2 WO2004113277A2 (fr) 2004-12-29
WO2004113277A8 true WO2004113277A8 (fr) 2005-07-14
WO2004113277A3 WO2004113277A3 (fr) 2005-10-13

Family

ID=33545555

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2004/002337 Ceased WO2004113277A2 (fr) 2003-06-23 2004-06-21 Procedes et compositions de traitement de maladies associees aux amyloides
PCT/IB2004/002375 Ceased WO2004113275A2 (fr) 2003-06-23 2004-06-21 Methodes et compositions pour traiter les maladies liees a l'amyloide

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002375 Ceased WO2004113275A2 (fr) 2003-06-23 2004-06-21 Methodes et compositions pour traiter les maladies liees a l'amyloide

Country Status (12)

Country Link
EP (2) EP1644325A2 (fr)
JP (2) JP2007516938A (fr)
KR (1) KR101124935B1 (fr)
AU (2) AU2004249529A1 (fr)
BR (1) BRPI0411743A (fr)
CA (2) CA2529256A1 (fr)
EA (1) EA012429B1 (fr)
MX (2) MXPA05014166A (fr)
NO (1) NO335084B1 (fr)
NZ (1) NZ544684A (fr)
UA (1) UA96115C2 (fr)
WO (2) WO2004113277A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2700212B2 (ja) 1990-09-14 1998-01-19 株式会社エース電研 金属センサおよびパチンコゲーム機
JP2660607B2 (ja) 1990-09-14 1997-10-08 株式会社エース電研 金属検知装置およびパチンコゲーム機
JP2660608B2 (ja) 1990-10-04 1997-10-08 株式会社エース電研 金属検知装置およびパチンコゲーム機
JP2700215B2 (ja) 1990-11-24 1998-01-19 株式会社エース電研 パチンコゲーム機
JP2700213B2 (ja) 1990-11-24 1998-01-19 株式会社エース電研 パチンコ玉検知装置およびパチンコゲーム機
JP2700214B2 (ja) 1990-11-24 1998-01-19 株式会社エース電研 パチンコゲーム機
EP1644325A2 (fr) * 2003-06-23 2006-04-12 Neurochem (International) Limited Methodes et compositions pour traiter les maladies liees a l'amyloide
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
EP1937239A2 (fr) * 2005-09-30 2008-07-02 Neurochem (International) Limited Méthodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques
CN101534826A (zh) 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
KR100883132B1 (ko) 2006-10-24 2009-02-10 재단법인서울대학교산학협력재단 아밀로이드 형성 펩타이드 또는 단백질의 가용성 회합체에선택적으로 작용하는 절단제
KR20090130022A (ko) 2007-03-07 2009-12-17 메사추세츠 인스티튜트 오브 테크놀로지 나노튜브 및 풀러렌을 포함하는 나노규모의 물품의 관능화
WO2008122030A2 (fr) * 2007-04-02 2008-10-09 University Of South Alabama Lavage au dioxyde de carbone utilisant des matières ioniques
EP2247558B2 (fr) 2008-02-14 2024-07-03 Eli Lilly and Company Nouveaux agents d'imagerie pour la détection d'une dysfonction neurologique
US8951473B2 (en) 2008-03-04 2015-02-10 Massachusetts Institute Of Technology Devices and methods for determination of species including chemical warfare agents
EP2326619B1 (fr) 2008-08-01 2019-02-27 Bioxiness Pharmaceuticals, Inc. Analogues de methionine, et procedes d'utilisation de ceux-ci
WO2010025375A1 (fr) * 2008-08-29 2010-03-04 Treventis Corporation Procédés de traitement d’une maladie amyloïde utilisant des analogues de 1-(4-nitrophényl)pipérazine
WO2010123482A2 (fr) 2008-12-12 2010-10-28 Massachusetts Institute Of Technology Structures à densité de charge élevée, comprenant des nanostructures à base de carbone et leurs applications
US8456073B2 (en) 2009-05-29 2013-06-04 Massachusetts Institute Of Technology Field emission devices including nanotubes or other nanoscale articles
MX2012001671A (es) 2009-08-10 2012-04-30 Bellus Health Inc Metodos, compuestos y composiciones para la administracion de acido 1,3-propanedisulfonico.
US8187887B2 (en) 2009-10-06 2012-05-29 Massachusetts Institute Of Technology Method and apparatus for determining radiation
KR101173677B1 (ko) * 2009-12-11 2012-08-13 한국과학기술연구원 Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
CN103003237B (zh) * 2010-07-28 2015-10-21 住友化学株式会社 氨基烷基硫代硫酸化合物的制造方法
US20120171093A1 (en) 2010-11-03 2012-07-05 Massachusetts Institute Of Technology Compositions comprising functionalized carbon-based nanostructures and related methods
MX380290B (es) 2015-08-10 2025-03-12 Alzheon Inc Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
JP6675167B2 (ja) 2015-08-28 2020-04-01 シスメックス株式会社 ペプチドの遊離方法及び回収方法、並びにペプチド遊離剤及び試薬キット
US9556301B1 (en) 2015-12-02 2017-01-31 King Fahd Universoty of Petroleum and Minerals Cyclopolymer containing residues of methionine and synthesis and uses thereof
WO2017150704A1 (fr) * 2016-03-04 2017-09-08 国立大学法人新潟大学 Activateur de la fonction de l'aquaporine 4 et composition pharmaceutique pour troubles neurologiques
RU2657844C1 (ru) * 2017-01-09 2018-06-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения экспериментальной амилоидной кардиопатии у крыс
WO2019090323A1 (fr) 2017-11-06 2019-05-09 Massachusetts Institute Of Technology Graphène à haute densité de fonctionnalisation
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020025066A1 (fr) * 2018-08-03 2020-02-06 The University Of Hong Kong Compositions et procédés de détection et d'imagerie de fibrilles amyloïdes, de plaques amyloïdes, d'arn et de nucléoles
JP7629182B2 (ja) * 2020-10-02 2025-02-13 Ｏ－Ｆｏｒｃｅ合同会社 アミロイドβの凝集抑制剤、アミロイドβ凝集疾患用医薬組成物、およびその用途
EP3992182A1 (fr) 2020-10-28 2022-05-04 Cisbio Bioassays Complexes d'europium(iii) en tant que capteurs de ph
CN116744912A (zh) * 2021-01-11 2023-09-12 苏州华明道康生物医药有限公司 取代的水杨酰胺化合物及其用途
CN113433325A (zh) * 2021-06-07 2021-09-24 西安市第一医院 血清vitronectin在AL型淀粉样变的诊断及疾病分期中的应用
US20250345298A1 (en) 2022-04-28 2025-11-13 Alzheon, Inc. Apoe4 correctors and methods of use
AU2023403257A1 (en) 2022-12-02 2025-06-12 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2376911A (en) * 1941-12-24 1945-05-29 Swiss Company Of Soc Of Chemic Derivatives of sulphonated amines and process of preparing same
DE927992C (de) * 1952-07-27 1955-05-23 Hoechst Ag Verfahren zur Herstellung von Salzen des 1, 2-Dimethyl-3-phenyl-4-amino-5-pyrazolons
US3453309A (en) * 1966-10-14 1969-07-01 Parke Davis & Co Phenylalkylaminoethyl thiosulfates
DE2140278A1 (en) * 1970-01-19 1972-03-09 Crompton and Knowles Corp., Worcester, Mass. (V.St.A.) Water-soluble dyes and dye intermediates
US4085134A (en) * 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
JPS60184564A (ja) * 1984-03-05 1985-09-20 Mitsui Toatsu Chem Inc 液晶に使用するジスアゾ系二色性染料、該染料を含む液晶組成物及び表示装置
DD287256A5 (de) * 1989-08-21 1991-02-21 Akademie Der Wissenschaften Der Ddr,De Verfahren zur herstellung von chiralen wasserloeslichen ammoniumalkansulfonsaeuren sowie deren salzen und sulfobetainen
JP3068841B2 (ja) * 1990-08-23 2000-07-24 日本臓器製薬株式会社 アミノアルカンスルホン酸誘導体を有効成分として含有する心疾患治療剤
JP3070687B2 (ja) * 1990-07-19 2000-07-31 日本臓器製薬株式会社 心疾患治療剤
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
JPH0995444A (ja) * 1995-10-02 1997-04-08 Teijin Ltd アミロイド蛋白凝集阻害剤
US6007819A (en) * 1995-10-17 1999-12-28 Dovetail Technologies, Inc. Methods of inducing immunity using low molecular weight immune stimulants
WO1998052563A1 (fr) * 1997-05-21 1998-11-26 Shionogi & Co., Ltd. REMEDES CONTRE LA DEMENCE DU TYPE ALZHEIMER CONTENANT DES DERIVES DE η-SULTAME
NZ514453A (en) * 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
EP1237547A2 (fr) * 1999-07-09 2002-09-11 Isis Innovation Limited Composes destines a l'inhibition de maladies et a la preparation de cellules a transplanter
JP4440446B2 (ja) * 1999-10-05 2010-03-24 花王株式会社 皮膚外用剤
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MXPA02005576A (es) * 1999-11-29 2002-12-13 Neurochem Inc Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
EP1251837A2 (fr) * 1999-12-23 2002-10-30 Neurochem, Inc. Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
AU2003292936A1 (en) * 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1644325A2 (fr) * 2003-06-23 2006-04-12 Neurochem (International) Limited Methodes et compositions pour traiter les maladies liees a l'amyloide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Also Published As

Publication number Publication date
NO335084B1 (no) 2014-09-08
CA2529256A1 (fr) 2004-12-29
CA2529257C (fr) 2013-04-23
JP2007516939A (ja) 2007-06-28
UA96115C2 (uk) 2011-10-10
WO2004113277A3 (fr) 2005-10-13
EP1644325A2 (fr) 2006-04-12
KR20060023172A (ko) 2006-03-13
AU2004249529A1 (en) 2004-12-29
JP2007516938A (ja) 2007-06-28
CA2529257A1 (fr) 2004-12-29
BRPI0411743A (pt) 2006-08-08
EA200600078A1 (ru) 2006-08-25
AU2004249527A1 (en) 2004-12-29
NZ544684A (en) 2009-10-30
MXPA05014166A (es) 2006-03-13
MXPA05013977A (es) 2006-03-09
WO2004113275A3 (fr) 2005-10-27
EA012429B1 (ru) 2009-10-30
WO2004113275A2 (fr) 2004-12-29
EP1658264A2 (fr) 2006-05-24
NO20055894L (no) 2006-03-21
KR101124935B1 (ko) 2012-04-12
WO2004113277A2 (fr) 2004-12-29
JP5146714B2 (ja) 2013-02-20

Similar Documents

Publication Publication Date Title
WO2004113277A8 (fr) Procedes et compositions de traitement de maladies associees aux amyloides
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2006085149A3 (fr) Methodes et compositions de traitement de maladies liees a l'amyloide
WO2006086562A3 (fr) Derives de phenylazetidinone
WO2005069865A3 (fr) Derives de pyrrolopyrimidine et analogues et utilisation dans le traitement et la prevention de maladies
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2005046603A3 (fr) Composes pyridiniques
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
EP1684758A4 (fr) Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies
WO2004112762A3 (fr) Formulations pharmaceutiques de composes inhibiteurs de substances amyloides
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2005000208A3 (fr) Therapie combinee pour le traitement des neoplasmes
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2006059252A3 (fr) Procedes et compositions fluorees pour le traitement de maladies associees aux amyloides
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
WO2007059341A3 (fr) Modulateurs de la proteine kinase a base de pyrazolothiazole
WO2004105696A3 (fr) Therapie combinatoire pour le traitement des neoplasmes
WO2005089294A3 (fr) Synthese d'indenoisoquinoliniums et techniques d'utilisation
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2004078142A3 (fr) Compositions et methodes de preventions et de traitement de maladies et d'etats pathologiques associes aux endotoxines
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2007069073A3 (fr) Formulations pharmaceutiques de composes inhibiteurs d'amyloide
WO2007010013A3 (fr) Composes organiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480024250.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 53/2004 UNDER (72, 75) REPLACE "KONG, YIANQI" BY "KONG, XIANQI"

WWE Wipo information: entry into national phase

Ref document number: 2004249527

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2529256

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/013977

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2004249527

Country of ref document: AU

Date of ref document: 20040621

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004249527

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006516597

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004743998

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 544682

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2004743998

Country of ref document: EP